ISF35

ISF35 (also known as Ad-ISF35 or AD-ISF35) is a gene therapy drug candidate consisting of an adenovirus vector encoding a membrane-bound engineered human CD154 chimeric protein. The therapy is designed to enhance immune-mediated killing of malignant B cells by expressing the improved version of CD154 (CD40 ligand) on their surface. This expression activates antigen-presenting cells and promotes immunoactivation through the CD40 pathway, leading to increased tumor cell apoptosis and a strong bystander effect that eradicates both transduced and non-transduced tumor cells. Preclinical studies have shown that intratumoral injection induces rapid infiltration of macrophages and neutrophils into tumors, upregulates proinflammatory cytokines in the tumor microenvironment, breaks immune tolerance, and results in durable local and systemic antitumor responses. Clinical trials have evaluated its safety and activity in patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas[1][3][4][5][6][7][8].

Brand names

ISF35ISF-35ISF 35

Other names

chimeric CD154engineered CD154